Obesity and prostate cancer: Is there a link?

e-SPEN Journal

Volumn 9, Issue 3, 2014, Pages

  Wooding, Alicia E ^a   Rehman, Ishtiaq ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Biological mechanisms; BMI; Obesity; Overweight; Prostate cancer

Indexed keywords

ADIPOCYTOKINE; ANDROGEN; INSULIN;

CANCER DIAGNOSIS; CANCER GROWTH; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE ASSOCIATION; HUMAN; NONHUMAN; OBESITY; PROSTATE CANCER; REVIEW; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84901485337     PISSN: None     EISSN: 22128263     Source Type: Journal    
DOI: 10.1016/j.clnme.2014.04.001     Document Type: Review

References (52)

1. WHO Obesity and overweight 2013, WHO: World Health Organization.
2. Statistics OfN Cancer statistics registrations, England (Series MB1) 2012, Office for National Statistics.
3. Blando J., Moore T., Hursting S., Jiang G., Saha A., Beltran L., et al. Dietary energy balance modulates prostate cancer progression in Hi-Myc mice. Cancer Prev Res (Phila) 2011, 2002-2014. [United States: 2011 Aacr].
4. Etzioni R., Penson D.F., Legler J.M., di Tommaso D., Boer R., Gann P.H., et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. JNatl Cancer Inst 2002, 94:981-990.
5. Parekh N., Lin Y., Dipaola R.S., Marcella S., Lu-Yao G. Obesity and prostate cancer detection: insights from three national surveys. Am J Med 2010, 829-835. [United States].
6. Wong J.R., Gao Z., Merrick S., Wilson P., Uematsu M., Woo K., et al. Potential for higher treatment failure in obese patients: correlation of elevated body mass index and increased daily prostate deviations from the radiation beam isocenters in an analysis of 1,465 computed tomographic images. Int J Radiat Oncol Biol Phys 2009, 49-55. [United States].
7. Hsing A.W., Chua S., Gao Y.T., Gentzschein E., Chang L., Deng J., et al. Prostate cancer risk and serum levels of insulin and leptin: a population-based study. JNatl Cancer Inst 2001, 93:783-789.
8. Burton A., Martin R.M., Holly J., Lane J.A., Donovan J.L., Hamdy F.C., et al. Associations of adiponectin and leptin with stage and grade of PSA-detected prostate cancer: the ProtecT study. Cancer Causes Control 2012, 1-12.
9. Armstrong A.J., Halabi S., de Wit R., Tannock I.F., Eisenberger M. The relationship of body mass index and serum testosterone with disease outcomes in men with castration-resistant metastatic prostate cancer. Prostate Cancer Prostatic Dis 2009, 88-93. [England].
10. Shaneyfelt T., Husein R., Bubley G., Mantzoros C.S. Hormonal predictors of prostate cancer: a meta-analysis. JClin Oncol 2000, 18:847-853.
11. Yadav N., Heemers H.V. Androgen action in the prostate gland. Minerva Urol Nefrol 2012, 64:35-49.
12. Taichman R.S., Cooper C., Keller E.T., Pienta K.J., Taichman N.S., McCauley L.K. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 2002, 62:1832-1837.
13. NICE CG58 Prostate cancer: NICE guidance 2008, NICE.
14. Fesinmeyer M.D., Gulati R., Zeliadt S., Weiss N., Kristal A.R., Etzioni R. Effect of population trends in body mass index on prostate cancer incidence and mortality in the United States. Cancer Epidemiol Biomarkers Prev 2009, 808-815. [United States].
15. Wolk A., Gridley G., Svensson M., Nyren O., McLaughlin J.K., Fraumeni J.F., et al. Aprospective study of obesity and cancer risk (Sweden). Cancer Causes Control 2001, 12:13-21.
16. Chamberlain C., Romundstad P., Vatten L., Gunnell D., Martin R.M. The association of weight gain during adulthood with prostate cancer incidence and survival: a population-based cohort. Int J Cancer 2011, 129:1199-1206.
17. Hernandez B.Y., Park S.Y., Wilkens L.R., Henderson B.E., Kolonel L.N. Relationship of body mass, height, and weight gain to prostate cancer risk in the multiethnic cohort. Cancer Epidemiol Biomarkers Prev 2009, 18:2413-2421.
18. Renehan A.G., Tyson M., Egger M., Heller R.F., Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008, 371:569-578.
19. MacInnis R.J., English D.R. Body size and composition and prostate cancer risk: systematic review and meta-regression analysis. Cancer Causes Control 2006, 17:989-1003.
20. Freedland S.J., Platz E.A., Presti J.C., Aronson W.J., Amling C.L., Kane C.J., et al. Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection. JUrol 2006, 175:500-504.
21. Baillargeon J., Pollock B.H., Kristal A.R., Bradshaw P., Hernandez J., Basler J., et al. The association of body mass index and prostate-specific antigen in a population-based study. Cancer 2005, 103:1092-1095.
22. Stamey T.A., Yang N., Hay A.R., McNeal J.E., Freiha F.S., Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. NEngl J Med 1987, 317:909-916.
23. Grubb R.L., Black A., Izmirlian G., Hickey T.P., Pinsky P.F., Mabie J.E., et al. Serum prostate-specific antigen hemodilution among obese men undergoing screening in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Epidemiol Biomarkers Prev 2009, 748-751. [United States].
24. Thompson I.M., Ankerst D.P., Chi C., Goodman P.J., Tangen C.M., Lucia M.S., et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. JNatl Cancer Inst 2006, 98:529-534.
25. Parker A.S., Thiel D.D., Bergstralh E., Carlson R.E., Rangel L.J., Joseph R.W., et al. Obese men have more advanced and more aggressive prostate cancer at time of surgery than non-obese men after adjusting for screening PSA level and age: results from two independent nested case-control studies. Prostate Cancer Prostatic Dis Dec 2013, 16(4):352-356.
26. Freedland S.J., Banez L.L., Sun L.L., Fitzsimons N.J., Moul J.W. Obese men have higher-grade and larger tumors: an analysis of the duke prostate center database. Prostate Cancer Prostatic Dis 2009, 259-263. [England].
27. Bassett J.K., Severi G., Baglietto L., MacInnis R.J., Hoang H.N., Hopper J.L., et al. Weight change and prostate cancer incidence and mortality. Int J Cancer 2012, 131:1711-1719.
28. Chamie K., Oberfoell S., Kwan L., Labo J., Wei J.T., Litwin M.S. Body mass index and prostate cancer severity: do obese men harbor more aggressive disease on prostate biopsy?. Urology 2013 May, 81(5):949-955.
29. Prostate cancer. Information about NICE clinical guideline 2008, 58.
30. Lindner U., Lawrentschuk N., Abouassaly R., Fleshner N.E., Trachtenberg J. Radical prostatectomy in obese patients: improved surgical outcomes in recent years. Int J Urol 2010, 727-732. [Australia].
31. Sumitomo M., Asakuma J., Yoshii H., Sato A., Horiguchi A., Ito K., et al. Anterior perirectal fat tissue thickness is a strong predictor of recurrence after high-intensity focused ultrasound for prostate cancer. Int J Urol 2010, 776-782. [Australia].
32. Freedland S.J., Aronson W.J., Kane C.J., Presti J.C., Amling C.L., Elashoff D., et al. Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the shared equal access regional cancer hospital database study group. JClin Oncol 2004, 22:446-453.
33. Cao Y., Ma J. Body mass index, prostate cancer-specific mortality, and biochemical recurrence: a systematic review and meta-analysis. Cancer Prev Res (Phila) 2011, 486-501. [United States: 2011 Aacr].
34. Ho T., Gerber L., Aronson W.J., Terris M.K., Presti J.C., Kane C.J., et al. Obesity, prostate-specific antigen nadir, and biochemical recurrence after radical prostatectomy: biology or technique? Results from the SEARCH database. Eur Urol 2012, 62:910-916.
35. Kok D.E.G., van Roermund J.G.H., Aben K.K., van de Luijtgaarden M.W.M., Karthaus H.F.M., van Trip O.B.V., et al. Body mass index is not a predictor of biochemical recurrence after radical prostatectomy in Dutch men diagnosed with prostate cancer. World J Urol 2011, 29:695-701.
36. Davies B.J., Smaldone M.C., Sadetsky N., Dall'era M., Carroll P.R. The impact of obesity on overall and cancer specific survival in men with prostate cancer. JUrol 2009, 112-117. [United States], discussion 7.
37. Sanda M.G., Dunn R.L., Michalski J., Sandler H.M., Northouse L., Hembroff L., et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. NEngl J Med 2008, 1250-1261. [United States: 2008 Massachusetts Medical Society].
38. Calle E.E., Rodriguez C., Walker-Thurmond K., Thun M.J. Overweight, obesity, andmortality from cancer in a prospectively studied cohort of U.S. adults. NEngl J Med 2003, 1625-1638. [United States: 2003 Massachusetts Medical Society].
39. Lai G.Y., Helzlsouer K.J., Clipp S.L., Rifai N., Platz E.A. Association between C-peptide concentration and prostate cancer incidence in the CLUE II cohort study. Cancer Prev Res (Philadelphia, Pa) 2010, 3:1334-1341.
40. Rowlands M.A., Holly J.M., Gunnell D., Gilbert R., Donovan J., Lane J.A., et al. The relation between adiposity throughout the life course and variation in IGFs and IGFBPs: evidence from the ProtecT (Prostate testing for cancer and Treatment) study. Cancer Causes Control 2010, 21:1829-1842.
41. Wright J.L., Plymate S., D'Oria-Cameron A., Bain C., Haugk K., Xiao L., et al. Astudyof caloric restriction versus standard diet in overweight men with newly diagnosed prostate cancer: a randomized controlled trial. Prostate 2013 Sep, 73(12):1345-1351.
42. Rowlands M.A., Gunnell D., Harris R., Vatten L.J., Holly J.M., Martin R.M. Circulating insulin-like growth factor peptides and prostate cancer risk: a systematic review and meta-analysis. Int J Cancer 2009, 124:2416-2429.
43. Ukkola O., Santaniemi M. Adiponectin: a link between excess adiposity and associated comorbidities?. JMol Med (Berl) 2002, 80:696-702.
44. Lu J.P., Hou Z.F., Duivenvoorden W.C., Whelan K., Honig A., Pinthus J.H. Adiponectin inhibits oxidative stress in human prostate carcinoma cells. Prostate Cancer Prostatic Dis 2012, 15:28-35.
45. Considine R.V., Sinha M.K., Heiman M.L., Kriauciunas A., Stephens T.W., Nyce M.R., et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. NEngl J Med 1996, 334:292-295.
46. Stattin P., Söderberg S., Hallmans G., Bylund A., Kaaks R., Stenman U.H., et al. Leptin is associated with increased prostate cancer risk: a nested case-referent study. JClin Endocrinol Metab 2001, 86:1341-1345.
47. Frankenberry K.A., Somasundar P., McFadden D.W., Vona-Davis L.C. Leptin induces cell migration and the expression of growth factors in human prostate cancer cells. Am J Surg 2004, 560-565. [United States].
48. Ribeiro A.M., Andrade S., Pinho F., Monteiro J.D., Costa M., Lopes C., et al. Prostate cancer cell proliferation and angiogenesis in different obese mice models. Int J Exp Pathol 2010, 374-386. [England].
49. Li H., Stampfer M.J., Mucci L., Rifai N., Qiu W., Kurth T., et al. A25-year prospective study of plasma adiponectin and leptin concentrations and prostate cancer risk and survival. Clin Chem 2010, 34-43. [United States].
50. Gross M., Ramirez C., Luthringer D., Nepomuceno E., Vollmer R., Burchette J., et al. Expression of androgen and estrogen related proteins in normal weight and obese prostate cancer patients. Prostate 2009, 69:520-527.
51. Cussenot O., Azzouzi A.R., Nicolaiew N., Fromont G., Mangin P., Cormier L., et al. Combination of polymorphisms from genes related to estrogen metabolism and risk of prostate cancers: the hidden face of estrogens. JClin Oncol 2007, 25:3596-3602.
52. Ramos-Nino M.E. The role of chronic inflammation in obesity-associated cancers. ISRN Oncol 2013, 2013:697521.